Intrinsic value of GW Pharmaceuticals Plc - GWPH

Previous Close

$168.83

  Intrinsic Value

$2.72

stock screener

  Rating & Target

str. sell

-98%

Previous close

$168.83

 
Intrinsic value

$2.72

 
Up/down potential

-98%

 
Rating

str. sell

We calculate the intrinsic value of GWPH stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 5.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  47.60
  43.34
  39.51
  36.06
  32.95
  30.15
  27.64
  25.38
  23.34
  21.50
  19.85
  18.37
  17.03
  15.83
  14.75
  13.77
  12.89
  12.10
  11.39
  10.75
  10.18
  9.66
  9.20
  8.78
  8.40
  8.06
  7.75
  7.48
  7.23
  7.01
Revenue, $m
  19
  28
  38
  52
  69
  90
  115
  145
  178
  217
  260
  307
  360
  417
  478
  544
  614
  688
  767
  849
  936
  1,026
  1,120
  1,219
  1,321
  1,428
  1,538
  1,653
  1,773
  1,897
Variable operating expenses, $m
  384
  547
  760
  1,031
  1,369
  1,779
  2,268
  2,842
  3,503
  4,254
  5,089
  6,024
  7,050
  8,166
  9,370
  10,660
  12,035
  13,492
  15,029
  16,645
  18,340
  20,111
  21,961
  23,888
  25,894
  27,981
  30,150
  32,404
  34,747
  37,181
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  384
  547
  760
  1,031
  1,369
  1,779
  2,268
  2,842
  3,503
  4,254
  5,089
  6,024
  7,050
  8,166
  9,370
  10,660
  12,035
  13,492
  15,029
  16,645
  18,340
  20,111
  21,961
  23,888
  25,894
  27,981
  30,150
  32,404
  34,747
  37,181
Operating income, $m
  -365
  -520
  -722
  -979
  -1,299
  -1,688
  -2,153
  -2,697
  -3,325
  -4,038
  -4,830
  -5,717
  -6,690
  -7,749
  -8,892
  -10,116
  -11,421
  -12,803
  -14,262
  -15,796
  -17,404
  -19,085
  -20,840
  -22,669
  -24,573
  -26,553
  -28,611
  -30,751
  -32,974
  -35,284
EBITDA, $m
  -344
  -493
  -688
  -935
  -1,244
  -1,619
  -2,066
  -2,590
  -3,195
  -3,882
  -4,652
  -5,507
  -6,445
  -7,465
  -8,566
  -9,745
  -11,002
  -12,334
  -13,739
  -15,217
  -16,766
  -18,385
  -20,076
  -21,838
  -23,672
  -25,579
  -27,562
  -29,623
  -31,765
  -33,990
Interest expense (income), $m
  1
  1
  8
  18
  31
  48
  68
  93
  122
  157
  196
  242
  293
  349
  411
  478
  551
  628
  711
  799
  892
  989
  1,091
  1,198
  1,309
  1,426
  1,547
  1,672
  1,803
  1,939
  2,080
Earnings before tax, $m
  -366
  -528
  -740
  -1,010
  -1,347
  -1,756
  -2,245
  -2,819
  -3,481
  -4,234
  -5,071
  -6,009
  -7,039
  -8,160
  -9,370
  -10,667
  -12,049
  -13,515
  -15,061
  -16,688
  -18,393
  -20,177
  -22,038
  -23,979
  -25,998
  -28,100
  -30,284
  -32,554
  -34,913
  -37,364
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -366
  -528
  -740
  -1,010
  -1,347
  -1,756
  -2,245
  -2,819
  -3,481
  -4,234
  -5,071
  -6,009
  -7,039
  -8,160
  -9,370
  -10,667
  -12,049
  -13,515
  -15,061
  -16,688
  -18,393
  -20,177
  -22,038
  -23,979
  -25,998
  -28,100
  -30,284
  -32,554
  -34,913
  -37,364

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  286
  411
  573
  779
  1,036
  1,348
  1,721
  2,158
  2,661
  3,233
  3,875
  4,587
  5,369
  6,218
  7,135
  8,118
  9,164
  10,274
  11,444
  12,675
  13,965
  15,315
  16,723
  18,190
  19,718
  21,307
  22,959
  24,675
  26,459
  28,313
Adjusted assets (=assets-cash), $m
  286
  411
  573
  779
  1,036
  1,348
  1,721
  2,158
  2,661
  3,233
  3,875
  4,587
  5,369
  6,218
  7,135
  8,118
  9,164
  10,274
  11,444
  12,675
  13,965
  15,315
  16,723
  18,190
  19,718
  21,307
  22,959
  24,675
  26,459
  28,313
Revenue / Adjusted assets
  0.066
  0.068
  0.066
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
  0.067
Average production assets, $m
  113
  161
  225
  306
  407
  530
  676
  848
  1,046
  1,271
  1,523
  1,803
  2,110
  2,444
  2,804
  3,190
  3,602
  4,038
  4,498
  4,982
  5,489
  6,019
  6,572
  7,149
  7,750
  8,374
  9,023
  9,698
  10,399
  11,128
Working capital, $m
  -34
  -48
  -67
  -92
  -122
  -159
  -203
  -254
  -314
  -381
  -457
  -541
  -633
  -733
  -841
  -957
  -1,080
  -1,211
  -1,349
  -1,494
  -1,646
  -1,805
  -1,971
  -2,144
  -2,324
  -2,511
  -2,706
  -2,908
  -3,118
  -3,337
Total debt, $m
  42
  90
  153
  233
  332
  454
  598
  768
  963
  1,185
  1,434
  1,710
  2,014
  2,343
  2,699
  3,080
  3,486
  3,917
  4,371
  4,848
  5,349
  5,873
  6,419
  6,988
  7,581
  8,198
  8,839
  9,505
  10,197
  10,916
Total liabilities, $m
  111
  159
  222
  302
  402
  523
  668
  837
  1,033
  1,255
  1,504
  1,780
  2,083
  2,413
  2,768
  3,150
  3,556
  3,986
  4,440
  4,918
  5,419
  5,942
  6,488
  7,058
  7,651
  8,267
  8,908
  9,574
  10,266
  10,985
Total equity, $m
  175
  251
  350
  477
  634
  825
  1,053
  1,320
  1,629
  1,979
  2,372
  2,807
  3,286
  3,806
  4,367
  4,968
  5,609
  6,288
  7,004
  7,757
  8,547
  9,373
  10,234
  11,132
  12,067
  13,040
  14,051
  15,101
  16,193
  17,328
Total liabilities and equity, $m
  286
  410
  572
  779
  1,036
  1,348
  1,721
  2,157
  2,662
  3,234
  3,876
  4,587
  5,369
  6,219
  7,135
  8,118
  9,165
  10,274
  11,444
  12,675
  13,966
  15,315
  16,722
  18,190
  19,718
  21,307
  22,959
  24,675
  26,459
  28,313
Debt-to-equity ratio
  0.240
  0.360
  0.440
  0.490
  0.520
  0.550
  0.570
  0.580
  0.590
  0.600
  0.600
  0.610
  0.610
  0.620
  0.620
  0.620
  0.620
  0.620
  0.620
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
  0.630
Adjusted equity ratio
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612
  0.612

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -366
  -528
  -740
  -1,010
  -1,347
  -1,756
  -2,245
  -2,819
  -3,481
  -4,234
  -5,071
  -6,009
  -7,039
  -8,160
  -9,370
  -10,667
  -12,049
  -13,515
  -15,061
  -16,688
  -18,393
  -20,177
  -22,038
  -23,979
  -25,998
  -28,100
  -30,284
  -32,554
  -34,913
  -37,364
Depreciation, amort., depletion, $m
  21
  27
  34
  44
  56
  70
  87
  107
  130
  156
  177
  210
  245
  284
  326
  371
  419
  470
  523
  579
  638
  700
  764
  831
  901
  974
  1,049
  1,128
  1,209
  1,294
Funds from operations, $m
  -345
  -501
  -706
  -967
  -1,291
  -1,686
  -2,159
  -2,712
  -3,351
  -4,078
  -4,894
  -5,800
  -6,794
  -7,876
  -9,044
  -10,296
  -11,630
  -13,045
  -14,538
  -16,108
  -17,755
  -19,477
  -21,274
  -23,147
  -25,097
  -27,126
  -29,235
  -31,426
  -33,704
  -36,070
Change in working capital, $m
  -11
  -15
  -19
  -24
  -30
  -37
  -44
  -51
  -59
  -67
  -76
  -84
  -92
  -100
  -108
  -116
  -123
  -131
  -138
  -145
  -152
  -159
  -166
  -173
  -180
  -187
  -195
  -202
  -210
  -218
Cash from operations, $m
  -334
  -487
  -687
  -942
  -1,261
  -1,650
  -2,115
  -2,661
  -3,292
  -4,011
  -4,819
  -5,716
  -6,702
  -7,776
  -8,936
  -10,180
  -11,507
  -12,914
  -14,400
  -15,963
  -17,603
  -19,318
  -21,108
  -22,974
  -24,917
  -26,939
  -29,040
  -31,224
  -33,493
  -35,852
Maintenance CAPEX, $m
  -9
  -13
  -19
  -26
  -36
  -47
  -62
  -79
  -99
  -122
  -148
  -177
  -210
  -245
  -284
  -326
  -371
  -419
  -470
  -523
  -579
  -638
  -700
  -764
  -831
  -901
  -974
  -1,049
  -1,128
  -1,209
New CAPEX, $m
  -36
  -49
  -64
  -81
  -101
  -123
  -146
  -172
  -198
  -225
  -252
  -280
  -307
  -334
  -360
  -386
  -411
  -436
  -460
  -484
  -507
  -530
  -553
  -577
  -600
  -624
  -649
  -675
  -701
  -729
Cash from investing activities, $m
  -45
  -62
  -83
  -107
  -137
  -170
  -208
  -251
  -297
  -347
  -400
  -457
  -517
  -579
  -644
  -712
  -782
  -855
  -930
  -1,007
  -1,086
  -1,168
  -1,253
  -1,341
  -1,431
  -1,525
  -1,623
  -1,724
  -1,829
  -1,938
Free cash flow, $m
  -379
  -549
  -769
  -1,050
  -1,397
  -1,820
  -2,323
  -2,911
  -3,589
  -4,357
  -5,219
  -6,173
  -7,219
  -8,355
  -9,580
  -10,893
  -12,289
  -13,769
  -15,330
  -16,970
  -18,689
  -20,486
  -22,361
  -24,315
  -26,349
  -28,464
  -30,663
  -32,948
  -35,322
  -37,790
Issuance/(repayment) of debt, $m
  36
  48
  63
  80
  100
  121
  145
  169
  195
  222
  249
  276
  303
  330
  356
  381
  406
  430
  454
  478
  501
  524
  546
  569
  593
  617
  641
  666
  692
  719
Issuance/(repurchase) of shares, $m
  423
  604
  839
  1,137
  1,504
  1,947
  2,473
  3,086
  3,789
  4,584
  5,464
  6,445
  7,517
  8,680
  9,931
  11,268
  12,690
  14,193
  15,778
  17,441
  19,183
  21,002
  22,900
  24,877
  26,933
  29,072
  31,295
  33,604
  36,005
  38,499
Cash from financing (excl. dividends), $m  
  459
  652
  902
  1,217
  1,604
  2,068
  2,618
  3,255
  3,984
  4,806
  5,713
  6,721
  7,820
  9,010
  10,287
  11,649
  13,096
  14,623
  16,232
  17,919
  19,684
  21,526
  23,446
  25,446
  27,526
  29,689
  31,936
  34,270
  36,697
  39,218
Total cash flow (excl. dividends), $m
  79
  104
  133
  167
  206
  249
  295
  345
  396
  449
  495
  548
  602
  655
  707
  757
  807
  855
  902
  948
  994
  1,040
  1,085
  1,131
  1,177
  1,224
  1,273
  1,323
  1,375
  1,428
Retained Cash Flow (-), $m
  -423
  -604
  -839
  -1,137
  -1,504
  -1,947
  -2,473
  -3,086
  -3,789
  -4,584
  -5,464
  -6,445
  -7,517
  -8,680
  -9,931
  -11,268
  -12,690
  -14,193
  -15,778
  -17,441
  -19,183
  -21,002
  -22,900
  -24,877
  -26,933
  -29,072
  -31,295
  -33,604
  -36,005
  -38,499
Prev. year cash balance distribution, $m
  296
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -47
  -500
  -706
  -969
  -1,298
  -1,699
  -2,178
  -2,742
  -3,393
  -4,135
  -4,970
  -5,896
  -6,915
  -8,025
  -9,225
  -10,511
  -11,883
  -13,339
  -14,876
  -16,493
  -18,188
  -19,963
  -21,815
  -23,746
  -25,756
  -27,848
  -30,022
  -32,282
  -34,630
  -37,070
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -45
  -458
  -615
  -798
  -1,006
  -1,233
  -1,472
  -1,714
  -1,949
  -2,168
  -2,360
  -2,516
  -2,629
  -2,694
  -2,708
  -2,671
  -2,586
  -2,456
  -2,290
  -2,096
  -1,881
  -1,656
  -1,430
  -1,209
  -1,002
  -812
  -644
  -499
  -378
  -279
Current shareholders' claim on cash, %
  73.8
  54.9
  41.1
  31.1
  23.6
  18.1
  13.9
  10.7
  8.3
  6.5
  5.1
  4.0
  3.2
  2.5
  2.0
  1.6
  1.3
  1.0
  0.8
  0.6
  0.5
  0.4
  0.3
  0.3
  0.2
  0.2
  0.1
  0.1
  0.1
  0.1

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

FINANCIAL RATIOS  of  GW Pharmaceuticals Plc (GWPH)

Valuation Ratios
P/E Ratio -319.2
Price to Sales 5106.4
Price to Book 151.1
Price to Tangible Book
Price to Cash Flow -381.1
Price to Free Cash Flow -331.6
Growth Rates
Sales Growth Rate -23.1%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 81.8%
Cap. Spend. - 3 Yr. Gr. Rate 17.3%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 1.8%
Total Debt to Equity 1.8%
Interest Coverage -184
Management Effectiveness
Return On Assets -33.3%
Ret/ On Assets - 3 Yr. Avg. -22.9%
Return On Total Capital -38.4%
Ret/ On T. Cap. - 3 Yr. Avg. -26.6%
Return On Equity -38.9%
Return On Equity - 3 Yr. Avg. -26.9%
Asset Turnover 0
Profitability Ratios
Gross Margin 60%
Gross Margin - 3 Yr. Avg. 73.6%
EBITDA Margin -1780%
EBITDA Margin - 3 Yr. Avg. -915.2%
Operating Margin -1860%
Oper. Margin - 3 Yr. Avg. -954.9%
Pre-Tax Margin -1850%
Pre-Tax Margin - 3 Yr. Avg. -951.6%
Net Profit Margin -1600%
Net Profit Margin - 3 Yr. Avg. -782.2%
Effective Tax Rate 13.5%
Eff/ Tax Rate - 3 Yr. Avg. 20.6%
Payout Ratio 0%

GWPH stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the GWPH stock intrinsic value calculation we used $13 million for the last fiscal year's total revenue generated by GW Pharmaceuticals Plc. The default revenue input number comes from 0001 income statement of GW Pharmaceuticals Plc. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our GWPH stock valuation model: a) initial revenue growth rate of 47.6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for GWPH is calculated based on our internal credit rating of GW Pharmaceuticals Plc, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of GW Pharmaceuticals Plc.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of GWPH stock the variable cost ratio is equal to 2023.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for GWPH stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 20.4% for GW Pharmaceuticals Plc.

Corporate tax rate of 27% is the nominal tax rate for GW Pharmaceuticals Plc. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the GWPH stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for GWPH are equal to 586.6%.

Life of production assets of 8.6 years is the average useful life of capital assets used in GW Pharmaceuticals Plc operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for GWPH is equal to -175.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $415.159 million for GW Pharmaceuticals Plc - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 30.593 million for GW Pharmaceuticals Plc is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of GW Pharmaceuticals Plc at the current share price and the inputted number of shares is $5.2 billion.

RELATED COMPANIES Price Int.Val. Rating
FLKS Flex Pharma, I 0.425 0.13  str.sell
GSK GlaxoSmithKlin 41.25 65.66  str.buy

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.